Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
AI generated
Aug 14, 2026, 23:14

Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring

Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:

“Avatrombopag in hematology – dosing and monitoring

Oral thrombopoietin-receptor agonist that promotes megakaryocyte proliferation and platelet production.

Main uses

  • Persistent or chronic immune thrombocytopenia after inadequate response to prior therapy
  • Severe thrombocytopenia in chronic liver disease before an invasive procedure
  • Not intended to normalize platelet counts
  • Evidence in aplastic anemia is evolving and remains off-label

Chronic ITP – adult dosing

  • Start 20 mg PO once daily with food
  • Target: lowest dose maintaining platelets greater than or equal to 50 ×10⁹/L
  • Maximum: 40 mg/day
  • Assess response only after at least 2 weeks before another adjustment

Dose ladder

  1. 20 mg once weekly
  2. 20 mg twice weekly or 40 mg once weekly
  3. 20 mg three times weekly
  4. 20 mg daily
  5. 40 mg three times weekly with 20 mg on remaining 4 days
  6. 40 mg daily

US-label adjustment

  • Platelets less than 50 after at least 2 weeks – increase one level
  • 200–400 – decrease one level
  • Greater than 400 – hold; CBC twice weekly
  • Restart one level lower when less than 150
  • Stop if less than 50 after 4 weeks at 40 mg/day
  • Stop if greater than 400 after 2 weeks at 20 mg/week

The EMA thresholds differ: reduce if greater than 150 to 250; hold if greater than 250 and restart one level lower when less than 100. Follow the locally approved product information.

Monitoring

  • CBC and platelet counts weekly until stable, then monthly.
  • Twice weekly after dose changes or when using once- or twice-weekly regimens
  • After discontinuation: weekly CBC for at least 4 weeks
  • Monitor bleeding and rebound thrombocytopenia
  • Assess thrombotic risk and symptoms: DVT/PE, arterial events and portal-vein thrombosis
  • Review concomitant ITP therapy to avoid an excessive platelet rise

Drug interactions

  • Dual CYP2C9 or CYP3A4 inhibitor – e.g. fluconazole: start 20 mg three times per week
  • Dual inducer – e.g. rifampicin: start 40 mg daily
  • No routine dose adjustment for mild – moderate renal or hepatic impairment; limited data in severe impairment

Chronic liver disease before procedure

  • Baseline platelets less than 40, use 60 mg daily for 5 days
  • Platelets 40 to less than 50, use 40 mg daily for 5 days
  • Start 10 – 13 days before procedure
  • Procedure 5 – 8 days after last dose
  • Check platelets before treatment and on procedure day
  • This is a fixed course – not chronic titration

Pearls

  • Take consistently with food
  • No polyvalent-cation separation requirement like eltrombopag
  • Do not double a missed dose
  • Do not chase a normal platelet count

MCQ: Platelets reach 430 ×10⁹/L on avatrombopag. Next step?

Hold treatment, monitor twice weekly and restart one level lower when below the label-defined threshold.

OSCE: Counsel regarding adherence, missed doses, bleeding, rebound thrombocytopenia and urgent symptoms of venous or arterial thrombosis.”

Other posts featuring Chokri Ben Lamine on Hemostasis Today.

aplastic anemia Avatrombopag Blood CBC Chokri Ben Lamine chronic liver disease CLD Eltrombopag Fluconazole Health Hematology Hemostasis Hemostasis News Hemostasis Today Immune thrombocytopenia ITP Medicine Megakaryocyte Proliferation Oral thrombopoietin-receptor agonist platelet production platelets rifampicin thrombocytopenia
NewsFeed